- 期刊
2012 Guidelines of the Taiwan Society of Cardiology (TSOC) for the Management of ST-Segment Elevation Myocardial Infarction
並列摘要
ST-segment elevation myocardial infarction (STEMI) is one of the most common cardio vascular diseases in Taiwan. The management strategies for STEMI are to do early diagnosis, minimize delay of medical contact, and administration of reperfusion therapy as rapidly as possible. Initial evaluation in emergency department for STEMI includes concise history taking, physical examination, electrocardiogram and cardiac biomarkers measurement. A 12-lead electrocardiogram should be performed within 10 minutes of emergency department arrival. Oxygen, nitroglycerin, analgesia, dual antiplatelet therapy and anticoagulation drugs should be given immediately. Patients with STEMI should receive reperfusion therapy either by primary percutaneous coronary intervention with door-to-balloon time within 90 minutes or by thrombolytic therapy with door-to-needle time within 30 minutes. The pharmacological treatment after admission includes antiplatelet drugs, anticoagulation drugs, beta blockers, angiotensin converting enzyme inhibitors/angiotensin receptor blockers and statins. STEMI patients should be watched out for hypotension, heart failure or even cardiogenic shock. Mechanical complications, such as acute mitral regurgitation, septum rupture and free wall rupture, cause high mortality after STEMI. Tachy-and bradyarrhythmias are also common in patients with STEMI and should be treated accordingly. Permanent cardiac pacing and implantable cardioverter defibrillator may be necessary after STEMI. Coronary artery bypass grafting surgery may be performed as a definitive or adjunctive revascularization therapy after STEMI. Surgery is also necessary if there are mechanical complications. Before discharge, cardiac rehabilitation should be considered when patients are stabilized. Referral for outpatient rehabilitation should also be encouraged. Antiplatelet drugs, beta blockers, angiotensin converting enzyme inhibitors/angiotensin receptor blockers and statins should be continued after discharge for secondary prevention. Effective hypertension, diabetes and lipid control are important after STEMI.
延伸閱讀
- Chiang, C. H., Huang, W. C., Yang, J. S., Cheng, C. C., Kuo, F. Y., Chiou, K. R., Lee, T. Y., Lin, T. W., Mar, G. Y., Chiou, C. W., Liu, C. P., & Lee, K. T. (2013). Five-Year Outcomes after Acute Myocardial Infarction in Patients with and without Diabetes Mellitus in Taiwan, 1996-2005. Acta Cardiologica Sinica, 29(5), 387-394. https://www.airitilibrary.com/Article/Detail?DocID=10116842-201309-201309180030-201309180030-387-394
- 李志偉、王志鴻、謝仁哲、施教諭、吳英黛、黃千惠（2009）。Risk Factors for Acute Myocardial Infarction among Eastern Taiwan Middle-age Male between 1993-1999 and 2000-2006。台灣醫學，13(5)，441-448。https://doi.org/10.6320/FJM.2009.13(5).02
- 林怡方（2019）。The Current Application of Taiwan Clinic Performance Indicator and Predictors of Prognosis in Acute Myocardial Infarction〔碩士論文，高雄醫學大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0011-0401201906094900
- Chiang, C. E., Hung, C. L., Wu, Y. W., Lin, T. H., Ueng, K. C., Sung, S. H., Wu, C. K., Chao, T. H., Lin, H. J., Lin, Y. H., Huang, J. L., Chen, M. Y. C., Lin, P. L., Chao, T. F., Cheng, H. M., Liu, M. E., Wang, T. D., Yeh, H. I., Li, Y. H., Liu, P. Y., Yin, W. H., Hsieh, I. C., Wang, C. C., Chen, C. H., Chu, P. H., Lin, S. J., Yeh, S. J., Lin, J. L., Hwang, J. J., Hung, H. F., Chen, W. J., & Hou, C. J. Y. (2023). 2023 Consensus of Taiwan Society of Cardiology on the Pharmacological Treatment of Chronic Heart Failure. Acta Cardiologica Sinica, 39(3), 361-390. https://doi.org/10.6515/ACS.202305_39(3).20230301A
- Chiang, C. E., Wang, T. D., Lin, T. H., Yeh, H. I., Liu, P. Y., Cheng, H. M., Chao, T. H., Chen, C. H., Shyu, K. G., Ueng, K. C., Chen, C. Y., Chu, P. H., Sung, S. H., Wang, K. L., Li, Y. H., Wang, K. Y., Chiang, F. T., Lai, W. T., Chen, J. H., Chen, W. J., Yeh, S. J., Chen, M. F., Lin, S. J., & Lin, J. L. (2017). The 2017 Focused Update of the Guidelines of the Taiwan Society of Cardiology (TSOC) and the Taiwan Hypertension Society (THS) for the Management of Hypertension. Acta Cardiologica Sinica, 33(3), 213-225. https://doi.org/10.6515/ACS20170421A